QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
NYSE:DNA

Ginkgo Bioworks (DNA) Stock Price, News & Analysis

$1.31
+0.02 (+1.55%)
(As of 02/22/2024 ET)
Today's Range
$1.29
$1.38
50-Day Range
$1.16
$1.80
52-Week Range
$1.12
$2.55
Volume
18.12 million shs
Average Volume
21.94 million shs
Market Capitalization
$2.78 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.20

Ginkgo Bioworks MarketRank™ Stock Analysis

Analyst Rating
Reduce
1.75 Rating Score
Upside/​Downside
67.9% Upside
$2.20 Price Target
Short Interest
Bearish
17.95% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.41mentions of Ginkgo Bioworks in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$1.31 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.42) to ($0.29) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.24 out of 5 stars

Medical Sector

757th out of 934 stocks

Biological Products, Except Diagnostic Industry

136th out of 160 stocks


DNA stock logo

About Ginkgo Bioworks Stock (NYSE:DNA)

Ginkgo Bioworks Holdings Inc. is a biotech company attempting to revolutionize the biotechnology industry by engineering completely new organisms. Founded in 2008 by Jason Kelly, Austin Che, Thomas Knight Jr. and Bartholomew Canton, the company operates a market-agnostic platform utilizing the latest technologies to pioneer the development of more sustainable biotechnology and bioengineering applications. 

Ginkgo Bioworks Holdings Inc. develops multiple platforms for food production, agriculture, industrial and pharmaceuticals. These platforms enable bioengineering applications across diverse markets, and the company customizes organisms for customers ranging from large companies to smaller startups. The company also creates proprietary software, algorithms and automation to engineer "customizable organisms" for their customers and the development of new products for the industrial and consumer markets. 

The company has earned multiple awards for its innovative technology in biologics, including the National Science Foundation's Innovation Corps Award, the National Academy of Engineering's Grand Challenges Award and the World Economic Forum's Technology Pioneers Award. 

Ginkgo Bioworks Holdings Inc. has partnered with prestigious organizations, including the Broad Institute of MIT, Harvard, Genomics England, the National Institutes of Health and the National Science Foundation's Innovation Corps to further their mission of making biotechnology more accessible to smaller and medium-sized organizations. 

Ginkgo Bioworks Holdings Inc. strives to revolutionize the biotech industry, attempting to pioneer the development of an ecosystem that will provide more sustainable and accessible biotechnology systems. With the help of innovative technology and strategic partnerships with prestigious organizations, Ginkgo Bioworks Holdings Inc. is well on its way to achieving this goal and making biotechnology more accessible to smaller and medium-sized organizations.

Ginkgo Bioworks Holdings Inc. has a market cap of approximately $2.97 billion, down from $3.98 in 2022. However, the company has seen rapid growth since 2020, increasing revenues from $3.8 million in 2017 to $313.8 million in 2022. 

DNA Stock Price History

DNA Stock News Headlines

DNA Apr 2024 1.500 call
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
DNA Mar 2024 0.500 call
DNA Apr 2024 2.000 call
DNA Mar 2024 1.500 put
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
DNA Feb 2024 2.000 call
Evaluating Ginkgo Bioworks Holdings: Insights From 4 Financial Analysts
Ginkgo Bioworks Expects To Meet FY23 Revenue Guidance Ranges
See More Headlines
Receive DNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ginkgo Bioworks and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
2/22/2024
Next Earnings (Estimated)
3/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Fax
N/A
Employees
1,292
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.20
High Stock Price Target
$3.00
Low Stock Price Target
$1.10
Potential Upside/Downside
+66.7%
Consensus Rating
Reduce
Rating Score (0-4)
1.75
Research Coverage
4 Analysts

Profitability

Net Income
$-2,104,930,000.00
Net Margins
-272.30%
Pretax Margin
-275.85%

Debt

Sales & Book Value

Annual Sales
$477.71 million
Book Value
$0.89 per share

Miscellaneous

Outstanding Shares
2,118,440,000
Free Float
1,799,612,000
Market Cap
$2.80 billion
Optionable
Optionable
Beta
1.29
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report














DNA Stock Analysis - Frequently Asked Questions

Should I buy or sell Ginkgo Bioworks stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ginkgo Bioworks in the last twelve months. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" DNA shares.
View DNA analyst ratings
or view top-rated stocks.

What is Ginkgo Bioworks' stock price target for 2024?

4 brokerages have issued twelve-month price targets for Ginkgo Bioworks' stock. Their DNA share price targets range from $1.10 to $3.00. On average, they predict the company's share price to reach $2.20 in the next twelve months. This suggests a possible upside of 67.9% from the stock's current price.
View analysts price targets for DNA
or view top-rated stocks among Wall Street analysts.

How have DNA shares performed in 2024?

Ginkgo Bioworks' stock was trading at $1.69 at the beginning of 2024. Since then, DNA shares have decreased by 22.5% and is now trading at $1.31.
View the best growth stocks for 2024 here
.

When is Ginkgo Bioworks' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our DNA earnings forecast
.

What guidance has Ginkgo Bioworks issued on next quarter's earnings?

Ginkgo Bioworks updated its FY 2023 earnings guidance on Wednesday, January, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $250.0 million-$260.0 million, compared to the consensus revenue estimate of $258.7 million.

Who are Ginkgo Bioworks' major shareholders?

Ginkgo Bioworks' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (11.15%), ARK Investment Management LLC (9.38%), Vanguard Group Inc. (6.27%), Sumitomo Mitsui Trust Holdings Inc. (2.75%), Nikko Asset Management Americas Inc. (2.75%) and Norges Bank (0.70%). Insiders that own company stock include Barry Canton, Christian O Henry, Jason R Kelly, Marie E Fallon, Marijn E Dekkers, Mark E Dmytruk, Reshma P Shetty and Shyam Sankar.
View institutional ownership trends
.

How do I buy shares of Ginkgo Bioworks?

Shares of DNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:DNA) was last updated on 2/22/2024 by MarketBeat.com Staff